Hyperfine (HYPR) said late Tuesday that it enrolled initial patients in a study that will assess the use of portable ultra-low-field magnetic resonance imaging, or MRI, in neurology offices.

The study will compare portable low-field MRI and conventional high-field MRI for pathology findings, clinical utility and patient experience, the company said.

Hyperfine said it plans to enroll 100 patients in the study and complete the trial by year-end.